---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-042341"
form_type: "8-K"
ticker: "FTRE"
cik: "0001965040"
company_name: "Fortrea Holdings Inc."
filed_at: "2025-09-22T23:59:59+00:00"
generated_at: "2026-05-17T06:01:23.460566+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Fortrea appoints William Sharbaugh as Class III director effective Sept 22, 2025

## Summary
- William Sharbaugh appointed to Fortrea Board as Class III director, effective Sept 22, 2025.
- Sharbaugh served as COO of PPD, Inc. from 2007-2021 and held roles at Bristol-Myers Squibb and Merck.
- No committee assignments yet; will receive standard non-employee director compensation per existing policy.
- Sharbaugh currently chairs Ora LLC and serves on boards of Launch Therapeutics, Alcami, and BioCare.

## SEC filing metadata
- accession: 0001628280-25-042341
- form_type: 8-K
- ticker: FTRE
- cik: 0001965040
- company_name: Fortrea Holdings Inc.
- filed_at: 2025-09-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1965040/000162828025042341/0001628280-25-042341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1965040/000162828025042341/ftre-20250919.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-042341
- JSON: https://secwatch.observer/filing/0001628280-25-042341.json
- Plain text: https://secwatch.observer/filing/0001628280-25-042341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.